Company statement

Novo Nordisk Expands Affordability Offering with $35 insulin program called MyInsulinRx^TM

PLAINSBORO, N.J., September 13, 2023 – Effective today, a $35.00 insulin option called MyInsulinRx^TM is available from Novo Nordisk Inc for eligible patients.  The program builds on existing Novo Nordisk insulin affordability options and is intended to further lower out-of-pocket costs for eligible people living with type 1 and type 2 diabetes.  MyInsulinRx^TM is a cash offer program in which eligible patients with a prescription, can get a 30-day supply (up to three vials or two packs of FlexPen^®/FlexTouch^®/PenFill^® pens) of any combination of current Novo Nordisk Inc. insulins for $35.  Studies and clinical experience suggest that amount is an adequate supply to cover the monthly needs of a vast majority of people with diabetes.

The Novo Nordisk insulins available through MyInsulinRx^TM include both pre-filled pens and vials of basal (long-acting), bolus (short-acting) and pre-mix insulins:  NovoLog^®, NovoLog^® Mix 70/30, Levemir^®, Tresiba^®, Fiasp^®, Novolin^® N, Novolin^® R, Novolin^® 70/30, Insulin Aspart, Insulin Aspart Protamine and Insulin Aspart Injectable Suspension Mix 70/30 and Insulin Degludec.  Patients can enroll in MyInsulinRx^TM at NovoCare.com where they will receive a digital savings offer that can be downloaded and printed, saved to a phone, or emailed to a valid email address. Patients can also receive this offer by calling 1.844.NOVO4ME (1.844.668.6463) or by texting ‘ENROLL’ to ‘24177’. This offer can be redeemed at most retail pharmacies. The savings offer is valid for the calendar year. 

At Novo Nordisk, we recognize that some patients find it difficult to pay for healthcare, including insulin. That’s why we remain committed to ensuring affordable access to insulins by reducing the burden of out-of-pocket costs, helping transform the complex pricing system and fostering better pricing predictability.

We continually review and revise our offerings as well as work with diverse stakeholders to create solutions for differing patient needs.  People living with diabetes are encouraged to access and learn more about our affordability programs at NovoCare.com